At this level, cancer initiation interrelates with mutations impairing the action of enhancer of zeste homolog 2 (EZH2), which participates in H3K27 methylation and is a part of polycomb repressive complex 2 (PRC2). This evidence concerns the gene EZH2 and cancer.